Skip to Main Content

Paper Details

Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer.
Nat Chem Biol
53
2018
AKT, AURKA, MLN8237, PI3K, breast cancer, breast cancers, mTOR, tumor
Author NameAffiliation
James T WebberUniversity of California San Francisco
Rebecca S LevinUniversity of California San Francisco
James E KorkolaCenter for Spatial Systems Biology, Oregon Health and Sciences University
Kevan M ShokatUniversity of California San Francisco
Kevan M ShokatHoward Hughes Medical Institute, University of California San Francisco
Andrei GogaUniversity of California San Francisco
John D GordanUniversity of California San Francisco
Sourav BandyopadhyayUniversity of California San Francisco
  • 1 - 8

Datasets

Release 1.2